Meeting
2013 ASCO Annual Meeting
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.
Authors
Mark P. Saunders
Christie Hospital NHS Foundation Trust, Withington, United Kingdom
Mark P. Saunders , Istvan Lang , Eugenio Marcuello , Vito Lorusso , Janja Ocvirk , Dongbok Shin , Derek J. Jonker , Stuart Osborne , Markus Loeffler , Daniel Waterkamp , David Cunningham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00484939
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3521)
DOI
10.1200/jco.2013.31.15_suppl.3521
Abstract #
3521
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
First Author: David Cunningham
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
First Author: Julien Taieb
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando